PJ-34

CHF 60.00
In stock
AG-CR1-0100-M0011 mgCHF 60.00
AG-CR1-0100-M0055 mgCHF 95.00
AG-CR1-0100-M02525 mgCHF 200.00
More Information
Product Details
Synonyms N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide . HCl
Product Type Chemical
Properties
Formula

C17H17N3O2 . HCl

MW 295.2 . 36.5
CAS 344458-15-7
Purity Chemicals ≥98% (NMR)
Appearance White to light brown powder.
Solubility Soluble in DMSO or water.
Identity Identity determined by 1H-NMR and MS.
InChi Key RURAZZMDMNRXMI-UHFFFAOYSA-N
Smiles Cl.CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Hygroscopic.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent, water soluble poly(ADP-ribose) polymerase (PARP) inhibitor. 
  • Inhibits peroxynitrite-induced cell necrosis. 
  • Shows significant, dose-dependent anti-inflammatory effects in a variety of local inflammation models. 
  • Provides cardioprotection by decreasing myocardial infarct size. 
  • Shows protective effects in models of stroke. 
  • Suppresses cell growth in liver cancer cells.
Product References
  1. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation: F. Garcia Soriano, et al.; Nat. Med. 7, 108 (2001) 
  2. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke: G.E. Abdelkarim, et al.; Int. J. Mol. Med. 7, 255 (2001) 
  3. Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase: J.G. Mabley, et al.; Inflamm. Res. 50, 561 (2001) 
  4. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure: P. Pacher, et al.; J. Am. Coll. Cardiol. 40, 1006 (2002) 
  5. Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents: P. Jagtap, et al.; Crit. Care Med. 30, 1071 (2002) 
  6. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor: R. Faro, et al.; Ann. Thorac. Surg. 73, 575 (2002) 
  7. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells: Oncol. Rep. 20, 567 (2008) 
  8. The role of PARP activation in glutamate-induced necroptosis in HT-22 cells: X. Xu, et al.; Brain Res. 1343, 206 (2010) 
  9. Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway: R. Vaschetto, et al.; Crit. Care 14, R45 (2010)
  10. Effect of parthanatos on ropivacaine-induced damage in SH-SY5Y cells: T. Zheng, et al.; Clin. Exp. Pharmacol. Physiol. 44, 586 (2017)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.